|
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|
Nov 2020
|
Annals of Oncology: Official Journal of the European Society for Medical Oncology
|
myelodysplastic syndromes (MDS)
|
|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
|
Nov 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease
|
Nov 2020
|
British Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
|
Nov 2020
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
|
myelodysplastic syndromes (MDS)
|
|
The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications
|
Nov 2020
|
Cells
|
myelodysplastic syndromes (MDS)
|
|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
|
Nov 2020
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
|
Oct 2020
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
|
Oct 2020
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology
|
myelodysplastic syndromes (MDS)
|
|
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study
|
Oct 2020
|
Therapeutic Advances in Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
